VCYT
Veracyte, Inc.43.22
-0.31-0.71%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms guide, details drivers
Q&A largely reaffirms prepared remarks on strong Decipher momentum and 2026 guidance, adding color on drivers like Afirma's v2 no-result benefits and Decipher share gains to reach the high end, absent PPCs. Management dismissed competitive concerns, noting no shift despite a rival's volume rebound, with Decipher at 33% penetration across NCCN risks. They detailed margin guide flexibility for Prosigna and TrueMRD launches, with room to invest more, and outlined MRD reimbursement via two codes for ~20,000 MIBC patients. Competition? Not seeing it. Bladder evidence builds cautiously without extra sales. Investors will watch launch traction amid confident tone.
Key Stats
Market Cap
3.42BP/E (TTM)
113.74Basic EPS (TTM)
0.38Dividend Yield
0%Recent Filings
8-K
10-K
FY2025 results
Veracyte posted FY2025 net income of $66.4 million, up sharply from $24.1 million in 2024, fueled by testing revenue surging 18% to $493 million on 170k tests reported—Decipher Prostate volumes rocketed 27% while Afirma grew 11%. Q4 momentum accelerated with Decipher hitting peak quarterly volumes, driving 19% full-year test growth despite French ops divestiture. Gross margins expanded on lab efficiencies, yet R&D ticked up 2% for MRD and Prosigna LDT launches eyed in 2026. Cash swelled to $413 million on $136 million operating inflows. Payer reimbursement volatility threatens quarterly collections.
8-K
Q4 revenue up 19%
Veracyte crushed Q4 2025 with total revenue up 19% to $140.6 million, testing revenue up 21% to $135.8 million, Decipher surging 27%. GAAP net income hit $41.1 million; ops cash flow reached $52.6 million. Reaffirmed 2026 revenue growth of 10-13% to $570-582 million. Veracyte SAS liquidation dragged biopharma revenue.
8-K
Veracyte's strong 2025 prelims
Veracyte released preliminary 2025 results on January 11, 2026, projecting full-year revenue of $515-$517 million, up 16%, with testing revenue at $491-$493 million and volume up 19% to 169,700 tests. Decipher volume surged 27% while Afirma grew 11%; adjusted EBITDA margin exceeded 25%. Guidance calls for 2026 revenue growth of 10-13% to $570-$582 million. Final figures await audit.
10-Q
Q3 FY2025 results
Veracyte posted Q3 revenue of $131.9M, up 14% y/y from $115.9M, driven by 17% testing revenue growth to $127.8M on 19% volume gains in Decipher Prostate and Afirma, while biopharma revenue cratered 74% post-French sub deconsolidation. Gross profit climbed 16% to $91.3M as testing costs rose in line; operating income doubled to $22.9M, diluted EPS held at $0.24 on 79.7M shares. Cash swelled to $315.6M plus $50.9M short-term investments, with YTD operating cash flow at $83.7M and FCF $77.8M (derived). French restructuring shed non-core drag. Patent suit versus Sonic Healthcare brews.
IPO
Website
Employees
Sector
Industry
ACUT
Accustem Sciences Inc.
0.70-0.05
AVCRF
Avricore Health Inc.
0.05+0.02
BDSX
Biodesix, Inc.
7.90+0.38
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CSTL
Castle Biosciences, Inc.
39.05+0.17
DGX
Quest Diagnostics Incorporated
178.66-5.45
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
IMDX
Insight Molecular Diagnostics I
5.10+0.08
VRAX
Virax Biolabs Group Limited
0.40-0.01